ArticleOdontology2026
Latistat-2 modulates apoptosis and differentiation of human dental pulp stem cells.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lysosomal acid lipase (LAL) plays essential roles in bone metabolism and stem/progenitor cell behaviours. Given its established role in skeletal and periodontal biology, the present study aims to determine the specific role of LAL in regulating the critical behaviours of dental pulp stem cells (DPSCs), including cell viability, proliferation, apoptosis, and differentiation ability. Cells were treated with a common LAL inhibitor, Lalistat-2. Cell viability was determined using a live/dead assay. Cell proliferation was examined using the MTT and colony-forming assays. Cell cycle progression and apoptosis were investigated. The in vitro mineralisation and intracellular lipid accumulation were detected using Alizarin Red S and Oil Red O staining, respectively. mRNA expression was examined by real-time polymerase chain reaction. A high-throughput RNA sequencing technique was used to profile mRNA expression. Lalistat-2 treatment dysregulated mRNA expression in DPSCs, with pathway analysis identifying changes in several KEGG pathways, including DNA replication, the Hippo pathway, the cell cycle, and the TGF-β signalling pathway. Lalistat-2 was non-toxic at low concentrations (1-50 µM), though 50 µM significantly impaired proliferation and colony formation by inducing apoptosis without altering overall cell cycle progression. Lalistat-2 had complex effects on differentiation: low concentrations (1-10 µM) enhanced in vitro mineralisation, while it consistently reduced adipogenic differentiation by decreasing lipid accumulation and marker gene expression. In conclusion, Lalistat-2 treatment induces apoptosis and suppresses adipogenic differentiation in DPSCs. Notably, low concentrations enhanced in vitro mineralisation, highlighting a complex, concentration-dependent effect on differentiation. These findings confirm LAL's critical role in DPSCs' homeostasis and regeneration and underscore the importance of their metabolic adaptability.
Indexed as
Identifiers
42230423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.